$70.98
0.00%
Nasdaq, Fri, Dec 13 2024
ISIN
US05465P1012
Symbol
AXNX

Key metrics

Market capitalization $3.63b
Enterprise Value $3.32b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 617.33
EV/Sales (TTM) EV/Sales 7.68
P/S ratio (TTM) P/S ratio 8.40
P/B ratio (TTM) P/B ratio 5.46
Revenue growth (TTM) Revenue growth 26.08%
Revenue (TTM) Revenue $431.90m
EBIT (operating result TTM) EBIT $-7.22m
Free Cash Flow (TTM) Free Cash Flow $5.37m
Cash position $345.23m
EPS (TTM) EPS $-0.11
P/S forward 8.00
EV/Sales forward 7.31
Short interest 7.31%
Show more

Is Axonics Modulation Technologies, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Axonics Modulation Technologies, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Axonics Modulation Technologies, Inc. forecast:

1x Buy
20%
4x Hold
80%

Analyst Opinions

5 Analysts have issued a Axonics Modulation Technologies, Inc. forecast:

Buy
20%
Hold
80%

Financial data from Axonics Modulation Technologies, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
432 432
26% 26%
100%
- Direct Costs 110 110
14% 14%
25%
322 322
31% 31%
75%
- Selling and Administrative Expenses 268 268
27% 27%
62%
- Research and Development Expense 47 47
41% 41%
11%
7.27 7.27
251% 251%
2%
- Depreciation and Amortization 14 14
13% 13%
3%
EBIT (Operating Income) EBIT -7.22 -7.22
33% 33%
-2%
Net Profit -5.66 -5.66
53% 53%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about Axonics Modulation Technologies, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Axonics Modulation Technologies, Inc. Stock News

Neutral
PRNewsWire
about one month ago
MARLBOROUGH, Mass. , Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.
Neutral
Business Wire
3 months ago
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder and fecal incontinence. The R20 neurostimulator is labeled for a functional life in the body of a...
Neutral
Business Wire
3 months ago
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the Central District of California. The jury found that Axonics does not infringe any of the three patents-in-suit. “A jury of our peers recognized that Axonics' proprietary...
More Axonics Modulation Technologies, Inc. News

Company Profile

Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.

Head office United States
CEO Raymond Cohen
Employees 797
Founded 2012
Website www.axonics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today